La société n’a malheureusement pas amélioré sa communication sur la politique de rémunération 2019 des dirigeants. Si le fait que les dirigeants sociaux ne soient pas rémunérés au titre de leur mandats sociaux, mais au titre d'un contrat de travail au sein de la société est sans doute la raison pour laquelle la société ne communique pas suffisamment d'information sur cette politique de rémunération 2019, il n’en demeure pas moins que cela ne respecte pas complètement l'esprit de la loi Sapin II, ce que nous regrettons.
De la même façon, on regrettera le manque de communication de la société sur les rémunérations variables attribuées au titre de l’exercice. En effet, celles-ci sont composées à la fois d’une prime d'intéressement et d’une prime sur objectif mais aucune information sur les modalités sous-jacentes d’attribution de ces primes n’est communiquée, ce qui ne permet pas aux actionnaires de comprendre comment sont déterminés les montants attribués.
AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Summary Marketline's Jaguar Animal Health, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Jaguar Animal Health, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competit...
The independent financial analyst theScreener just awarded an improved star rating to AB SCIENCE (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date November 8, 2019, the closing price was EUR 4.23 and its expected value was estimated at EUR 3.88.
In general, Stora Enso is in compliance with the Finnish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 10 the board of directors requests an advisory vote on the Company’s executive remuneration policy. ECGS notes that this is the first time that Stora Enso puts its executive remuneration policy to a vote, which it strongly welcomes. Although ECGS has some concerns with regard to Stora Enso’s remuneration policy, the proposed structure is basically in line with its guidelines. Accordingly, ECGS recommends to vote FOR. Under ITEM 11 the shar...
In general, DSV Panalpina (formerly DSV, see below) is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 5.5 it is proposed to re-appoint Ms. Malou Aamund as Member of the board of directors. Although she is considered independent, ECGS has concerns over her aggregate time commitments. In view of these concerns, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead. ECGS notes that DSV completed the acquisition of Panalpina W...
La communication de la société sur son actionnariat est très peu transparente en n'étant faite que par seuils. Ce type de communication ne correspond pas aux pratiques de place. Nous notons l'absence de résolution relative aux rémunérations des dirigeants mandataires sociaux. Ceci est regrettable car les montants en jeux sont pourtant raisonnables: 174 342 € pour M. Gérard Tremblay, Président Directeur Général, et 176 815 € pour M. Yves Boulot, Directeur Général Délégué. Par ailleurs, la société ne communique pas le nombre de réunions tenues par le Conseil, ni le taux de présence de ses admi...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.